Fig. 4: Transcriptomic, proteomic and metabolic analysis for BCAA catabolism and TCA cycle in our cohort and GSE26566.
From: Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma
a Summary of the BCAA degradation pathway with 38 genes in our cohort and GSE26566. Clustering of the tissue samples below and genes to the right. Red and green indicate increases and decreases, respectively. b BCAT1 mRNA levels in 3‒9 tumour samples and a normal sample per case. The blue and grey bars represent tumour and normal samples, respectively. c Western blotting for the evaluation of BCAT1 and BCAT2 expression in the normal and tumour samples of all ten cases. d Immunohistochemical detection of BCAT1 and BCAT2 in the representative FS1 case of ICC. Original magnification: ×200. T tumour tissue, N normal liver tissue. Western blotting of the ICC samples. Quantification of immunohistochemical detection. e Metabolites include 2_Hydroxyglutarate, lactate, valine, leucine and isoleucine in 3‒4 tumour samples and one normal sample per case. The blue and grey bars represent tumour and normal samples, respectively. TCA, tricarboxylic acid.
